Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
STAR-LLD well tolerated with no dose-related toxicity or adverse eventsSTAR LLD achieved 90% bioavailability across all dosesPlasma levels showed a...
RESEARCH TRIANGLE PARK, N.C., July 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
Prospective, observational study to assess the clinical utility of the SCOUT® Radar Localization System (SCOUT) in real-world practiceSOUTH JORDAN, Utah,...
∙ Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected...
CV8102 recommended dose identified; expansion trial to confirm safety, tolerability, and efficacy Trial expansion focuses on advanced melanoma, an indication of...
Blockchain technology was originally designed to facilitate the safe transfer and storage of bitcoin, the world’s first and most popular...
Ideagen’s PleaseReview will improve review, co-authoring and redaction projects linked to cancer and other oncology treatments US-based pharmaceutical company, Immunomedics, is...